RASSF1 and laryngotracheoesophageal cleft: The analysis of sputum samples of participants from the NELSON trial, demonstrated that, while sputum cytology did not detect any LC patients, a 3-gene panel, comprising RASSF1A, 3OST2 and PRDM14, detected 28% of cases 2 years before the diagnosis (126).